Lactiplantibacillus plantarum P9 for chronic diarrhea in young adults: a large double-blind, randomized, placebo-controlled trial

Ni Yang, Teng Ma, Yong Xie, Qiong Li, Yingmeng Li, Longjin Zheng, Yalin Li, Qiuping Xiao, Zhihong Sun, Kexuan Zuo, Lai-Yu Kwok, Nonghua Lu (), Wenjun Liu () and Heping Zhang ()
Additional contact information
Ni Yang: Hohhot
Teng Ma: Hohhot
Yong Xie: The First Affiliated Hospital of Nanchang University
Qiong Li: State Key Laboratory for the Modernization of Classical and Famous Prescriptions of Chinese Medicine
Yingmeng Li: Hohhot
Longjin Zheng: State Key Laboratory for the Modernization of Classical and Famous Prescriptions of Chinese Medicine
Yalin Li: Hohhot
Qiuping Xiao: State Key Laboratory for the Modernization of Classical and Famous Prescriptions of Chinese Medicine
Zhihong Sun: Hohhot
Kexuan Zuo: State Key Laboratory for the Modernization of Classical and Famous Prescriptions of Chinese Medicine
Lai-Yu Kwok: Hohhot
Nonghua Lu: The First Affiliated Hospital of Nanchang University
Wenjun Liu: State Key Laboratory for the Modernization of Classical and Famous Prescriptions of Chinese Medicine
Heping Zhang: Hohhot

Nature Communications, 2024, vol. 15, issue 1, 1-17

Abstract: Abstract Current treatments for chronic diarrhea have limited efficacy and several side effects. Probiotics have the potential to alleviate symptoms of diarrhea. This randomized, double-blind, placebo-controlled trial evaluates the effects of administering the probiotic Lactiplantibacillus plantarum P9 (P9) strain in young adults with chronic diarrhea (Clinical Trial Registration Number: ChiCTR2000038410). The intervention period lasts for 28 days, followed by a 14-day post-intervention period. Participants are randomized into the P9 (n = 93) and placebo (n = 96) groups, with 170 individuals completing the double-blind intervention phase (n = 85 per group). The primary endpoint is the diarrhea symptom severity score. Both intention-to-treat (n = 189) and per-protocol (n = 170) analyses reveal a modest yet statistically significant reduction in diarrhea severity compared to the placebo group (20.0%, P = 0.050; 21.4%, P = 0.048, respectively). In conclusion, the results of this study support the use of probiotics in managing chronic diarrhea in young adults. However, the lack of blood parameter assessment and the short intervention period represent limitations of this study.

Date: 2024
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-024-51094-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-51094-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-51094-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().